KR20030025805A - Device for gradually emitting a volatile drug and air conditioner employing same - Google Patents

Abstract

PURPOSE: To provide a volatile medicine controlled release member capable of equalizing and controlling volatile release of medicine at a low concentration release speed, preventing unnecessary release by sufficiently dealing with a humidity change, and having a structure wherein a volatile volume is hardly affected even when a liquid volume of the medicine falls. CONSTITUTION: The volatile medicine controlled release member is provided with a container with an interior filled with liquid medicine, a liquid absorber comprising a medium for sucking up the medicine, a space part for filling an interior with the medicine volatilized from the liquid absorber, and a humidity sensitive film with a permeation amount of the medicine changing in response to the humidity change. The medicine is sucked up and volatilized by the liquid absorber, and it is controllably released from the humidity sensitive film in response to the humidity change while it is retained at certain concentration in the space part formed by the liquid absorber and the humidity sensitive film.

Description

Volatile chemical sustained release member and air conditioner using same {DEVICE FOR GRADUALLY EMITTING A VOLATILE DRUG AND AIR CONDITIONER EMPLOYING SAME}

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a volatilized drug sustained-release member which gradually releases a volatilized drug in response to a change in humidity. It is widely applicable in the field which wants to prevent this breeding. For example, it is applicable to a bathroom, a dressing room, a shoe rack, a food storage, a barn, an underground storage, a humidification passage for air conditioning of a building, a ventilation passage, etc. It is especially effective in keeping the indoor unit of an air conditioner clean.

Various techniques for slowly releasing the filled liquid phase over a long time have been proposed in various ways. In general, it is a method of impregnating into a porous material material and gradually volatilizing according to the capillary phenomenon. The porous material may be an inorganic compound such as zeolite or silica gel, or a foam or bundle of fibers of polypropylene, polyester or cellulose. In addition, Japanese Patent Application Laid-Open No. Hei 5-176733 and Japanese Patent Laid-Open No. Hei 6-40890 have also been proposed to enclose a small pore of an organic substance called cyclodextrin and gradually release it. In addition, the method of embodying sustained release by microencapsulation is also disclosed in Japanese Patent Application Laid-Open Nos. 6-9377, 6-65064, 7-89848, 9-911 and 9-12447. And Japanese Patent Laid-Open No. 9-57091.

In the case of using the suction body, a method frequently used in the insect repellent repellent or air freshener field is to heat the suction body with a heater to further improve the volatilization rate. Japanese Patent Application Laid-Open Nos. 55-57502, 63-240738, etc. It is proposed.

However, with the above conventional configuration, it was not possible to stably release a low concentration of volatilizing agent in accordance with external humidity change. In the initial stage of a large amount of drug, a large amount of drug is volatilized, and as time passes, the amount of the drug tends to be gradually reduced by the change in the weight of the drug.

The present invention is a volatilized drug sustained-release member capable of slowly releasing a drug by averaging and volatilizing the drug at a low concentration of release rate, and can sufficiently cope with a change in humidity, thereby suppressing unnecessary release. . In addition, even if the amount of the drug is reduced, the amount of volatilization is less affected.

1 is a front view of the volatilized drug sustained release member of Example 1. FIG.

Figure 2 is a side cross-sectional configuration of the volatilized drug sustained release member of Example 1.

FIG. 3 is a front sectional configuration view of the volatilized drug sustained release member in A line of FIG. 2. FIG.

4 is a cross-sectional view of an indoor unit of the air conditioner of Example 1;

5 is a front appearance view of the volatilized drug sustained release member of Example 2. FIG.

Figure 6 is a side cross-sectional configuration of the volatilized drug sustained release member of Example 2.

7 is a front appearance view of the volatilized drug sustained release member of Example 3. FIG.

Figure 8 is a side cross-sectional configuration of the volatilized drug sustained release member of Example 3.

9 is a front appearance view of the volatilized drug sustained release member of Example 4. FIG.

10 is a side cross-sectional view of the volatilized drug sustained release member of Example 4. FIG.

* Explanation of symbols for main parts of the drawings

1: arylisothiocyanate 2: container

3: polypropylene nonwoven fabric sheet 4: humidity sensitive film

5: space part 8: heat exchanger

9 heat exchanger 10 cross fan

11: outlet 17: volatile drug sustained release member

In accordance with the above object, there is provided a container filled with a medicament as a liquid, a liquid absorber for inhaling the medicament, a space for filling the medicament volatilized from the liquid absorber, and a change in humidity from the space. Therefore, it is a volatilized drug sustained-release member provided with the humidity sensitive film which changes the permeation | transmission amount of the said chemical | medical agent.

According to the above constitution, after the volatilizing agent is sucked from the container by the liquid absorber, the volatilized component is filled in the space part having a constant volume, and the gas-liquid equilibrium between the liquid surface of the liquid absorber and the space part is reached. Is saturated. If the external humidity is low and the drug is not released to the outside from the space portion, it can be controlled to be below the saturated vapor pressure concentration state, and the amount released to the outside can be suppressed. In addition, when the external humidity is high, the drug, which is volatilized and filled, passes through the humidity-sensitive film and is released to the outside. In this manner, a volatilized sustained release member excellent in releasing a low concentration of the medicament in accordance with humidity can be provided. Specifically, it is effective for the purpose of releasing about 100 mg / day at 30 ° C. and 95% relative humidity. In addition, since the chemical agent is indirectly vaporized into a space filled with a liquid absorber and then discharged to the outside, the chemicals of the liquid absorber are separated from the space by the gas-liquid equilibrium between the liquid surface of the liquid absorber and the space. The concentration change can be suppressed small.

The invention described in claim 1 includes a container filled with a medicine as a liquid, a liquid absorber for sucking the medicine, a space for filling the medicine volatilized from the liquid absorber, and a space from the space. It is a volatilized drug sustained-release member provided with the humidity sensitive film whose permeation | transmission amount of the said chemical | medical agent changes with a change of humidity.

The invention described in claim 2 is an air conditioner provided with the volatile chemically controlled sustained member in an indoor unit having at least a heat exchanger and an indoor fan for blowing air regulated by the heat exchanger into the room.

The invention described in claim 3 is a volatilized drug sustained release member in which the liquid absorber is a polypropylene foam or a polypropylene nonwoven fabric, and an air conditioner using the same.

The invention described in claim 4 is a volatilized drug sustained release member in which the liquid absorber is a sintered body of ceramics, and an air conditioner using the same.

The invention described in claim 5 is a volatilized sustained release member in which the drug is arylisothiocyanate, tea tree oil, eucalyptus oil, and an air conditioner using the same.

The invention described in claim 6 is a volatilized chemical sustained release member having a laminated structure in which the humidity sensitive film comprises viscose processed paper, and an air conditioner using the same.

Invention of Claim 7 is the volatilization sustained-release member which is 20-200 mg / day at 30 degreeC and 95% of a relative humidity, and the air conditioner using this.

The invention described in claim 8 is a volatilized drug sustained release member having a release amount of the drug of 10 mg / day or less at 30 ° C and a relative humidity of 30%, and an air conditioner using the same.

The invention described in claim 9 is a volatilized drug sustained release member which is a container having transparency capable of visualizing an internal liquid amount, and an air conditioner using the same.

The invention described in claim 10 is a volatilized-release sustained-release member having a structure in which the non-breathable film is exposed by welding a non-breathable film to the upper surface of the humidity-sensitive film, and the humidity-sensitive film is exposed, and the same It is an air conditioner.

The invention according to claim 11, wherein the container and the liquid absorber are separated from a portion constituted by the space portion and the humidity sensitive film, or the container is used as the liquid absorber, the space part and the humidity sensitive film. Volatile chemical sustained release member which can be separated from the structure and the air conditioner using the same.

Invention of Claim 12 is the air conditioner arrange | positioned so that the said humidity sensitive film surface may face the upstream side surface of the said heat exchanger.

EMBODIMENT OF THE INVENTION Hereinafter, embodiment of this invention is described, referring drawings.

(Example 1)

1 is a front external view of the volatilized drug sustained release member showing the present embodiment, FIG. 2 is a side cross-sectional configuration diagram of the volatilized drug sustained release member, and FIG. It is also. 1 is a aryl isothiocyanate to be a drug, 2 is a container formed of a colorless transparent polyethylene terephthalate (PET) for filling it, and 3 is a polypropylene nonwoven sheet for inhaling the aryl isothiocyanate by capillary action ( As a sheet, it is 0.8 g / ml in bulk density, and is arrange | positioned so that the end of a sheet may reach | attain the bottom part of the container 2. As shown in FIG. 4 is a humidity sensitive film in which viscose processed paper is laminated on polyethylene. What formed the viscose film | membrane with the application amount of 5 g / m <^{2> through} the rayon / pulp nonwoven fabric on the polyethylene sheet and 80 micrometers was used. 5 is a space part formed of the polypropylene nonwoven fabric sheet 3 and the humidity sensitive film 4. The arylisothiocyanate 1 is sucked by the polypropylene nonwoven sheet 3, and volatilized by the vapor pressure characteristic with respect to the ambient temperature, finally bringing the space portion 5 to the saturated vapor pressure concentration. This is a gas-liquid equilibrium relationship between the arylisothiocyanate liquid contained in the portion of the polypropylene nonwoven sheet 3 protruding toward the space portion 5 and the arylisothiocyanate vapor present in the space portion 5. As a result, the concentration is maintained. For example, since the vapor pressure of the aryl isothiocyanate is about 5 mmHg at 25 ° C, the saturated vapor concentration in the space portion is about 6600 ppm. When the humidity is low by the humidity sensitive film 4, vapor release of the aryl isothiocyanate is suppressed, so that the space portion 5 is continuously maintained at the saturated vapor pressure concentration. However, when the humidity becomes high, the aryl isothiocyanate vapor passes through the humidity sensitive film 4 and is released to the outside. The humidity sensitive film 4 has a loose structure due to swelling of the membrane structure due to the change of humidity, and the aryl isothiocyanate molecules permeate and are easily released to the outside. In order to make up for this discharge amount, the arylisothiocyanate 1 sucked from the polypropylene nonwoven sheet 3 is further volatilized to the space 5. At this time, when the rate of arylisothiocyanate release from the humidity sensitive film 4 to the outside and the rate of arylisothiocyanate volatilization from the polypropylene nonwoven sheet 3 to the space portion 5 are compared, Since it is fast in most cases, there is no shortage of release of arylisothiocyanates. By the volatilized drug sustained release member having such a configuration, it becomes possible to continuously release the drug from the humidity-sensitive film at a temperature of 30 ° C. and 95% relative humidity to about 100 mg / day. Next, the case where the volatilization sustained release member by this Example is used for the indoor unit of an air conditioner is demonstrated.

4 is a cross-sectional configuration diagram of an indoor unit of the air conditioner according to the present embodiment. The indoor air is sucked through the suction grilles 6 and 7, and the sucked air is cooled and dehumidified by the heat exchangers 8 and 9, and then sucked and blown by a cross flow fan 10. , To provide a cold wind to the interior space from the final outlet (11). Up and down deflection vanes 12 are provided in the discharge port 11 to control the discharge direction to the indoor space. At this time, the condensed water dehumidified by the heat exchangers 8 and 9 moves along the heat exchanger aluminum fins to reach the drain pan portions 13 and 14. The drain pan section 13 is configured as an integral part in the indoor unit frame 15, and the drain pan part 14 is configured as an integral part in the discharge grill 16. The condensed water accumulated in the drain pan portion 13 flows toward the drain pan portion 14 through the frame 15 and is finally discharged to the outside via a drain port (not shown). The aluminum fin of the heat exchanger 8 and 9 is equipped with the structure in which the vertical slit was formed in order to raise the efficiency of heat exchange performance. Therefore, the condensed water forms a water film at the slit part by surface tension, and thus it is difficult to directly drop into the drain pan parts 13 and 14, so that the speed at which the aluminum fin is dried becomes slow. do. For example, in an environmental atmosphere of 25 ° C. and 90% relative humidity, several ten hours are required for the heat exchanger aluminum fin to be dried, and it is hardly dried. At this time, the indoor unit space, particularly the inside of the blower circuit constituted by the heat exchangers 8 and 9, is exposed to an atmosphere having a relative humidity of 95% or more, which is an environmental condition in which mold is easily proliferated. 17 is a volatilization chemical | medical agent sustained | release member, arrange | positioned in the lower upstream side adjacent to the heat exchanger 9, and the humidity sensitive membrane 4 side of the volatilization chemical | medical agent sustained-release member 17 was set so that the heat exchanger may face each other. Accordingly, after the cooling and dehumidification operation stops, the upper and lower deflection blades 12 are in a closed state, and when the air in the high humidity state fills the entire indoor unit and reaches the humidity sensitive film 4, the volatile chemical sustained release member ( In the inside of 17), the aryl isothiocyanate 1 diffuses to the heat exchanger 9 side and passes between the aluminum fins, so that the upper and lower deflection blades 12 are in a closed state. It gradually spreads and accumulates in the space part etc. which were comprised by it. As a result, the inside of the indoor unit can retain 1 ppm or more of arylisothiocyanate vapor in the space at the bottom of the space constituted by the heat exchangers 8 and 9 and in the space of the upper low concentration. The high concentration of aryl isothiocyanate vapor remaining in the space portion 5 of the volatilization chemically-released member 17 penetrates the humidity sensitive film 4 and diffuses into the space 500-5000 times. Since the threshold of aryl isothiocyanate is about 10 ppm, it is the retention concentration of a level which does not feel an odor. As a result, sufficient fungicidal effect was obtained for common molds such as Cladosporium, Alternaria, Aspergillus, Penicillium, and Rhizopus in the interior space. Since the liquid amount of the chemical | medical agent uses transparent PET resin as a container, a user can easily confirm a weight loss state at any time by visual observation, and can make it easy to judge the exchange time to change.

(Example 2)

5 is a front external view of the volatilized drug sustained release member showing the present embodiment, and FIG. 6 is a side cross-sectional configuration diagram of the volatilized drug sustained release member. 18 is an arylisothiocyanate, 19 is a container formed of colorless transparent PET for filling it, 20 is a polypropylene foam having a continuous bubble for inhaling the arylisothiocyanate by capillary action, The density is 0.8 g / ml, 21 is a humidity sensitive film laminated with viscose processed paper on polyethylene, and has the same structure as in Example 1, and 22 is an aryl isothiocyanate supported and vaporized while supporting the deposited humidity sensitive film 21. It is a container for forming the space portion 23 for filling. The container 19 and the container 22 are separable, and by pushing the container 19 into the container 22, the container 19 is fitted into a fitting structure, so that the outer circumferential contact portion of the container 19 is the contact portion of the container 22. The airtightness of the container 19 and the container 22 is maintained by being inscribed in. In addition, the polypropylene foam 20 is structured to fit in the container 19, and it is arrange | positioned so that the bottom of the container 19 may be reached and the aryl isothiocyanate which was reduced may also be sucked in.

The arylisothiocyanate 18 is sucked by the polypropylene foam 20 and volatilized by vapor pressure with respect to the ambient temperature, finally bringing the space 23 to the saturated vapor pressure concentration. This is the relationship of the gas-liquid equilibrium between the arylisothiocyanate liquid contained in the portion of the polypropylene foam 20 protruding toward the space 23 and the arylisothiocyanate vapor present in the space 23. As a result, the concentration is maintained. Since the emission is suppressed when the humidity is low by the humidity sensitive film 21, the space 23 is continuously maintained at the saturated vapor pressure concentration. However, when the humidity is high, the aryl isothiocyanate 18 is released from the humidity sensitive film 21 to the outside. In order to make up for this release amount, the arylisothiocyanate 18 sucked by the polypropylene foam 20 is further volatilized. The amount of liquid change of the aryl isothiocyanate 18 can be easily confirmed by visually observing the container 19, and when it is determined that the replacement time is changed, the container 19 is separated from the container 22. Then, the container 19 prepared as a replacement part is filled with the aryl isothiocyanate 18, and the component in the state where the polypropylene foam 20 is sandwiched is again fitted with the container 22, thereby providing a volatile chemical. The sustained release member can be completed. Accordingly, the container 22 supporting the humidity sensitive film 21 becomes reusable again and again. The volatilization and release performance of the volatilized drug sustained release member is almost unchanged from that of Example 1.

(Example 3)

7 is a front external view of the volatilized drug sustained release member showing the present embodiment, and FIG. 8 is a side cross-sectional configuration diagram of the volatilized drug sustained release member. 24 is an arylisothiocyanate, 25 is a container formed of colorless transparent PET to fill it, 26 is a polypropylene foam with continuous bubbles for inhaling the arylisothiocyanate by capillary action, volume density 0.8 g / ml, where 27 is a humidity sensitive film laminated with viscose processed paper in polyethylene, and has the same structure as in Example 1, 28 is to support the deposited humidity sensitive film 27 and at the same time to fill the volatized arylisothiocyanate It is a container for forming the space 29 for. The container 25 and the container 28 are separable, and the container 25 is fitted into the fitting structure by pushing the container 25 into the container 28 so that the inner circumferential contact portion of the container 25 is the contact portion of the container 28. The airtightness of the container 25 and the container 28 is maintained by being externally circumscribed. In addition, the polypropylene foam 26 has a support structure which is to be inserted into the container 25. In this embodiment, the polypropylene foam 26 becomes a liquid absorbent together with the container 28 supporting the humidity sensitive film 27 ( 26) to be reusable again and again. The volatile isotropic sustained-release member can be completed by preparing what the container 25 filled with the aryl isothiocyanate 24 as replacement parts, and fitting the container 25 with the container 28 again.

In Example 2, a space composed of a container filled with a medicament as a liquid and a liquid absorber serving as a medium for sucking the medicament includes a space portion and a humidity change for filling the medicament volatilized from the liquid absorber therein. The structure which can be isolate | separated from the part comprised by the humidity sensitive film whose permeation | transmission amount of the said chemical | medical agent changes according to this is shown, In Example 3, the container part which filled the chemical | medical agent which is liquid inside is a liquid used as a medium for inhaling the said chemical | medical agent The structure which can be isolate | separated from the part comprised by the moisture sensitive film which changes the permeation | transmission amount of the said chemical | medical agent by the humidity part and the space part for filling the absorber and the said chemical | medical agent volatilized from the said liquid absorber inside is shown. This reusable portion can be reused as much as possible to provide a volatilized drug sustained release member in consideration of the environment.

(Example 4)

9 is a front external view of the volatilized drug sustained release member showing the present embodiment, and FIG. 10 is a side cross-sectional configuration diagram of the volatilized drug sustained release member. 30 is arylisothiocyanate, 31 is a container formed of colorless transparent PET for filling it, 32 is a ceramic sintered body for sucking arylisothiocyanate by capillary action, and has a volume density of 1.5 g / ml, 33 Is a humidity sensitive film laminated | stacked viscose processed paper on polyethylene, and is the structure similar to Example 1, and 34 is the space part formed by the ceramic sintered compact 32 and the humidity sensitive film 33. As shown in FIG. 35 is a non-breathable film having a polyethylene / nylon / aluminum foil / polyethylene structure, and is ultrasonically welded to the container 31 so as to cover the humidity sensitive film 33 to prevent leakage of the arylisothiocyanate 30. A part of the non-breathable film 35 has an intentional extension from the container 31, and has the structure which is easy to peel off the non-breathable film 35 with this extension. In use, the following functions can be achieved by peeling off the non-breathable film 35 from a volatilization sustained release member. The arylisothiocyanate 30 is sucked by the ceramic sintered body 32 and volatilized by vapor pressure with respect to the ambient temperature, finally bringing the space portion 34 to the saturated vapor pressure concentration. By the humidity sensitive film 33, since the emission is suppressed when the humidity is low, the space 34 continues to be maintained at the saturated vapor pressure concentration. However, when the humidity is high, the aryl isothiocyanate 30 is released from the humidity sensitive film 33 to the outside. In order to compensate for this discharge amount, the arylisothiocyanate 30 sucked from the ceramic sintered body 32 is further volatilized.

In the Example, a colorless transparent PET resin was used as a container for filling a drug, but the present invention is not limited thereto. In addition, in consideration of chemical resistance with a medicine to be filled, a material having no problem may be selected. In addition to this, a polypropylene resin, a polycarbonate resin, a polyethylene naphthalate resin, a polyethylene resin, a methyl pentene resin, etc. can be used so that the liquid amount of a chemical | medical agent can be visually confirmed easily. However, PET resin can be easily used as a container for a volatilized sustained release member by forming a sheet-like thing by press working, so that it can be obtained at low cost.

In the Example, although the polypropylene nonwoven fabric sheet, the polypropylene foam, and the ceramic sintered compact were used as a liquid absorber, what can be used by this invention is not limited to this. There is no particular problem as long as the material is suitable for inhaling the medicine. In addition, the chemical volatilization performance as the volatilizing drug sustained-release member is controlled by the gas-liquid equilibrium relationship between the drug contained in the liquid absorber portion protruding toward the space portion and the drug vapor present in the space portion, thereby reducing the concentration of the drug. When it is desired to volatilize, it is effective to reduce the amount of the medicine contained in the liquid absorber portion protruding toward the space portion, and to reduce the volume of the space portion filled with the chemical vapor.

Moreover, since this invention intends to discharge | release at low concentration what consists of plant essential oils, etc., it is thought that which is more preferable is excellent in lipophilic.

Although only aryl isothiocyanate was used in the said Example, what can be used by this invention is not limited to this. Tea tree oil, eucalyptus oil, etc. can be used. Moreover, as long as it is a chemical | medical agent which can acquire antibacterial and antifungal effect by the low concentration of volatilization amount, it can use as a chemical | medical agent of the volatilization sustained-release member of this invention.

Although the thing formed with the polyethylene / nylon / aluminum foil / polyethylene structure was used as a non-breathable film in the Example, what can be used by this invention is not limited to this. Generally, however, as a non-breathable film, the laminated structure film which consists of aluminum foil as an inner layer is used. Moreover, in this invention, it is preferable that it is excellent in the ultrasonic welding property with resin used as the container of a volatilization drug sustained release member.

In the Example, only the case where it applies to the indoor unit of a general type | mold separate type air conditioner was demonstrated, The use of the volatilization sustained release member by this invention is not limited to this. It can be widely used in fields such as fluctuations of seasons or atmospheric humidity conditions at that time, to prevent mold and bacteria from propagating. For example, it can be used in bathrooms, dressing rooms, shoe racks, food storage, barns, and underground storage. It is also applicable to humidification passages, ventilation passages, and the like for controlling building air.

As is clear from the above embodiment, according to the invention described in claim 1, after the volatilizing agent is sucked from the container by the liquid absorber, the volatilized component is filled in a space part having a constant volume, and the liquid surface of the liquid absorber is The gas-liquid equilibrium with the space portion is reached and saturated. If the external humidity is low and the drug is not released to the outside from the space portion, it can be controlled to the saturated vapor pressure concentration state or less, and the amount released to the outside can be suppressed. In addition, when the external humidity is high, the drug, which is volatilized and filled, passes through the humidity-sensitive film and is released to the outside. Thus, it is possible to provide a volatile drug sustained release member excellent in releasing a low concentration of the drug in accordance with the humidity. Specifically, it is effective for the purpose of releasing about 100 mg / day at 30 ° C. and 95% relative humidity. In addition, since the drug is indirectly vaporized into a space filled with a liquid absorber and then discharged to the outside, the change in concentration in the space is suppressed small by the gas-liquid equilibrium with the space even if the amount of the drug is gradually reduced or reduced. can do.

According to the invention described in claim 2, since undesired release of the medicament can be suppressed in a season of low humidity, and the medicament can be released slowly and steadily at a low concentration in a season of high humidity or in an atmosphere, the mold is kept inside the indoor unit. Breeding can be prevented for a long time.

According to the invention described in claim 3, by using the polypropylene foam or the polypropylene nonwoven fabric as the liquid absorber, sufficient suction capacity can be ensured.

According to the invention described in claim 4, by making the ceramic sintered body a liquid absorbent body, sufficient suction capacity can be ensured.

According to the invention described in claim 5, by using aryl isothiocyanate, tea tree oil, and eucalyptus oil as an agent, it is possible to provide an environmentally friendly antibacterial and antifungal effect at low concentration using natural ingredients.

According to invention of Claim 6, the humidity sensitive film which is sensitive to humidity can be provided by using the humidity sensitive film which is a laminated structure formed including viscose processed paper.

According to the invention as set forth in claim 7, the release amount of the drug is 20 to 200 mg / day at 30 ° C. and 95% relative humidity, depending on the type of drug, but gradually released at a level equal to or lower than that of the human threshold. Since the objective effect of a chemical | medical agent can be acquired, a favorable impression can also be given to a user.

According to the invention described in claim 8, when the release amount of the drug is 10 mg / day or less at 30 ° C. and 30% of the relative humidity, the release of unnecessary drugs in the low humidity condition can be suppressed, so that the replacement period can be extended. .

According to the invention described in claim 9, by using a container having transparency capable of visualizing the liquid amount inside, the liquid amount of the drug can be easily visually checked, and the user can be notified of the replacement time.

According to the invention described in claim 10, a non-breathable film is deposited on the surface of the humidity-sensitive film to form an exterior, and in use, the moisture-sensitive film is exposed by peeling off the non-breathable film. It can provide the minimum amount of simple packaging required.

According to the invention as set forth in claim 11, by distinguishing the volatilizable drug sustained-release member into a replaceable part and a non-removable part, active use of the reusable part can be achieved, and an environment-friendly member can be provided. have.

According to the invention described in claim 12, the humidity sensitive film surface of the volatilized drug sustained release member is directed to the heat exchanger side, whereby a rise in humidity at the heat exchanger side can be detected quickly, and the sustained response of the drug can be improved.

Claims (12)

A container filled with a drug as a liquid, a liquid absorber for sucking the drug, a space for filling the drug volatilized from the liquid absorber, and a permeation amount of the drug according to a change in humidity from the space. A volatilized drug sustained-release member provided with this humidity sensitive film which changes. An indoor unit having at least a heat exchanger and an indoor fan for blowing air regulated by the heat exchanger into the room, wherein the volatile chemical sustained release member is provided. The volatilized drug sustained release member according to claim 1 or 2, wherein the liquid absorber is a polypropylene foam or a polypropylene nonwoven fabric, and an air conditioner using the same. The volatilized drug sustained release member according to claim 1 or 2, wherein the liquid absorber is a ceramic sintered body, and an air conditioner using the same. The volatilized drug sustained release member according to any one of claims 1 to 4, wherein the drug is arylisothiocyanate, tea tree oil, eucalyptus oil, and an air conditioner using the same. The volatilized-release pharmaceutical sustained release member according to any one of claims 1 to 5, wherein the humidity sensitive film is a laminated structure including viscose processed paper, and an air conditioner using the same. The volatilized drug sustained release member according to any one of claims 1 to 6, wherein the drug release amount is 20 to 200 mg / day at 30 ° C and a relative humidity of 95%, and an air conditioner using the same. 8. The volatilized drug sustained release member according to any one of claims 1 to 7, wherein the drug release amount is 10 mg / day or less at 30 占 폚 and 30% relative humidity, and an air conditioner using the same. The volatilized drug sustained release member according to any one of claims 1 to 8, wherein the container is a container having transparency capable of visualizing an internal liquid amount, and an air conditioner using the same. The humidity-sensitive film according to any one of claims 1 to 9, wherein the moisture-sensitive film is exposed by welding a non-breathable film on the surface of the humidity-sensitive film to form an exterior, and peeling off the non-breathable film. A volatilized drug sustained release member, and an air conditioner using the same. The said container and the said liquid absorber are isolate | separable from the part comprised by the said space part and the said humidity sensitive film, or the said container is a said liquid absorber and the said space part in any one of Claims 1-10. And a volatilized drug sustained release member, which is separated from a portion constituted by the humidity sensitive film, and an air conditioner using the same. The air conditioner according to claim 2, wherein the humidity sensitive film surface is disposed to face the upstream side of the heat exchanger.